910 abstracts found.



Results filter

Clinical response, PFS and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in CheckMate 069 study

Year:

Session type: ,

Stephen Hodi1,Michael Postow2,Jason Chesney3,Anna Pavlick4,Caroline Robert5,Kenneth Grossmann6,David McDermott7,Gerald Linette8,Nicolas Meyer9,Jeffrey Giguere10,Sanjiv Agarwala11,Montaser Shaheen12,Marc Ernstoff13,David Minor14,April Salama15,Matthew Taylor16,Patrick Ott1,Christine Horak17,Paul Gagnier18,Jedd Wolchok2

1Dana-Farber Cancer Institute, Boston, MA, USA,2Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,3J. Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA,4New York University, Perlmutter Cancer Center, New York, NY, USA,5Gustave, Roussy and Paris-Sud University, Villejuif-Paris-Sud, France,6Huntsman Cancer Institute, Salt Lake City, UT, USA,7Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA,8Washington University, St. Louis, MO, USA,9Institut Universitaire du Cancer, Toulouse, France,10Greenville Health System, Greenville, SC, USA,11St. Luke’s Cancer Center, Bethlehem, PA, USA,12University of New Mexico, Albuquerque, NM, USA,13Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA,14California Pacific Melanoma Center, San Francisco, CA, USA,15Duke University, Durham, NC, USA,16Oregon Health & Science University, Portland, OR, USA,17Bristol-Myers Squibb, Princeton, NJ, USA,18Bristol-Myers Squibb, Wallingford, CT, USA


Young patients with HER2+ breast cancer rarely have a germline mutation in a known cancer predisposition gene

Year:

Session type: , ,

Diana Eccles1,Li Na2,Tom Maishman1,Ellen Copson1,Ian Campbell2

1University of Southampton, Southampton, UK,2Peter Macallum Cancer Centre, Melbourne, Australia


Childbearing patterns and ovarian cancer in the Million Women Study: variation by histological subtype

Year:

Session type: ,

Kezia Gaitskell1,Jane Green1,Kirstin Pirie1,Gillian Reeves1,Valerie Beral1,on behalf of the Million Women Study Collaborators1

1Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK


Longitudinal single cell clonal analysis reveals evolutionary stasis and predetermined malignant potential in non-dysplastic Barrett’s Oesophagus

Year:

Session type: , ,

Pierre Martinez1,Margriet R. Timmer2,Chiu T. Lau2,Sybren L. Meijer2,Fiebo J.W. ten Kate2,Rosalie C. Mallant-Hent3,9,Anton H.J. Naber4,9,Arnoud H.A.M. van Oijen5,9,Lubbertus C. Baak6,9,Pieter Scholten7,9,Clarisse J.M. Böhmer8,9,Paul Fockens2,Jacques J.G.H.M. Bergman2,9,Carlo C. Maley10,11,Trevor A. Graham1,Kausilia K. Krishnadath2,9

1Barts Cancer Institute – Queen Mary University of London, London, UK,2Academic Medical Center – University of Amsterdam, Amsterdam, The Netherlands,3Department of Gastroenterology and Hepatology, Flevoziekenhuis, Almere, The Netherlands,4Department of Gastroenterology and Hepatology, Tergooiziekenhuizen, Hilversum, The Netherlands,5Department of Gastroenterology and Hepatology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands,6Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands,7Department of Gastroenterology and Hepatology, Sint Lucas Andreas Ziekenhuis, Amsterdam, The Netherlands,8Department of Gastroenterology and Hepatology, Spaarne Ziekenhuis, Hoofddorp, The Netherlands,9Gastroenterological Association, Amsterdam, The Netherlands,10Center for Evolution and Cancer, University of California at San Francisco, San Francisco, CA, USA,11Biodesign Institute, School of Life Sciences, Arizona State University, Tempe, AZ, USA


Using germline susceptibility testing to inform the treatment of newly-diagnosed cancer patients

Year:

Session type:

Mark Robson1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Introduction: Genomic instability and cancer: Lessons from analysis of Bloom’s syndrome

Year:

Session type:

Ian Hickson1
1University of Copenhagen, Copenhagen, Denmark

Regulation of recombination-mediated DSB repair and its importance for genome stability

Year:

Session type:

Stephen West1
1London Research Institute, South Mimms, UK

The human mismatch repair interactome

Year:

Session type:

Josef Jiricny1
1Institute of Molecular Cancer Research, Zurich, Switzerland

The BRCA1-BRCA2 pathway of homologous recombination

Year:

Session type:

Simon Powell1
1Memorial Sloan-Kettering, New York, USA

Introduction: Lung cancer treatment: We have lift off!

Year:

Session type:

Marianne Nicolson1
1Aberdeen Royal Infirmary, Aberdeen, UK

Population-based data on lung cancer from the UK: The National Audit and beyond

Year:

Session type:

Michael Peake1
1Glenfield Hospital, Leicester, UK

Modern radiotherapy techniques and progress in non-small cell lung cancer

Year:

Session type:

Suresh Senan1
1VU University Medical Center, Asterdam, The Netherlands

Patient-specific mathematical radiation oncology: Integrating clinical imaging and modeling to improve outcomes

Year:

Session type:

Kristin Swanson1
1University of Washington, Seattle, WA, USA

Introduction: Genomics analysis of intratumour heterogeneity and drug resistance mechanisms in cancer medicine

Year:

Session type:

Charles Swanton1
1CR-UK London Research Institute, London, UK

Breast cancer intratumour heterogeneity: A challenge for personalised medicine

Year:

Session type:

James Hicks1
1Cold Spring Harbor Laboratory

Dissecting mechanisms of cancer drug resistance through functional genetics

Year:

Session type:

Rene Bernards1
1Netherlands Cancer Institute, Amsterdam, The Netherlands

Intratumoural heterogeneity and the evolution of drug resistance in high-grade serous ovarian cancer

Year:

Session type:

James Brenton1
1Cancer Research UK Cambridge Research Institute, Cambridge, UK

Introduction: Genetic predisposition to cancers – future implications for selective screening, surveillance and management

Year:

Session type:

Ros Eeles1
1ICR, Sutton, UK

Predicting cancer risk using genetic variation

Year:

Session type:

Douglas Easton1
1University of Cambridge, Cambridge, UK

Genetic predisposition to cancer – implications for selective screening

Year:

Session type:

Harry de Koning1
1Erasmus MC & Johns Hopkins Bloomberg School of Public Health, Rotterdam, The Netherlands

Adaptive trial design that incorporates biomarkers

Year:

Session type:

Lucinda Billingham1
1MRC Midland Hub for Trials Methodology Research & Cancer Research UK Clinical Trials Unit, University of Birmingham

Introduction: Cancer awareness and early diagnosis: International perspectives

Year:

Session type:

Amanda Ramirez1
1King's College London, London, UK

International differences in cancer awareness and beliefs: The International Cancer Benchmarking Partnership

Year:

Session type:

Lindsay Forbes1
1King's College London, London, UK

Cancer awareness and early diagnosis in Denmark: A rewarding intervention?

Year:

Session type:

Peter Vedsted1
1Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Denmark

Public attitudes and awareness of cancer risks and early detection: a Canadian perspective

Year:

Session type:

Heather Bryant1
1Canadian Partnership Against Cancer, Toronto, ON, Canada

Introduction: The first century of human tumour virology

Year:

Session type:

Chris Boshoff1
1University College London Cancer Institute

Introduction: Clinical and translational approaches to radiotherapy

Year:

Session type:

Gillie McKenna1
1Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, UK

Lessons from the small DNA tumour viruses

Year:

Session type:

Daniel DiMaio1
1Yale University School of Medicine, New Haven, CT, USA

Strategies for radiosensitisation targetting the tumour microenvironment

Year:

Session type:

Ruth Muschel1
1University of Oxford, Oxford, UK

Mechanisms of human papillomavirus-induced malignancy

Year:

Session type:

Lawrence Banks1
1International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

The role of functional imaging in developing strategies towards a patient-tailored approach in prostate cancer

Year:

Session type:

Karin Haustermans1
1University Hospital, Leuven, Belgium

Mechanisms of Epstein-Barr virus lymphomagenesis

Year:

Session type:

Martin Rowe1
1University of Birmingham, Birmingham, UK

Introduction: Deregulated expression of the translation machinery in cancer

Year:

Session type:

Robert White1
1Beatson Institute for Cancer Research, Glasgow, UK

Translating the PI3K/mTOR pathway and translational control to radiation therapy

Year:

Session type:

Robert Schneider1
1New York, NY, New York, NY, USA

Translational control of pancreatic carcinogenesis

Year:

Session type:

Stéphane Pyronnet1
1INSERM U1037, Toulouse, France

Deregulation of gene expression at the level of translation in diffuse large B-cell lymphoma

Year:

Session type:

Anne Willis1
1MRC Toxicology Unit, Leicester, UK

Introduction: Biomarker validation and adaptive clinical trial design

Year:

Session type:

Caroline Dive1
1Paterson Institute for Cancer Research, Manchester, UK

Fit-for-purpose biomarker validation

Year:

Session type:

Howard Scher1
1Memorial Sloan-Kettering Cancer Center

Biomarkers in early drug development

Year:

Session type:

Josep Tabernero1
1Val d'Hebron University Hospital, Barcelona, Spain

Direct and indirect actions of PI 3-kinase in cancer

Year:

Session type:

Bart Vanhaesebroeck1
1Barts Cancer Centre, London, UK

Introduction: Prognostication in advanced cancer: How and why?

Year:

Session type:

John Ellershaw1
1University of Liverpool & Marie Curie Palliative Care Institute

Promising new drugs in lymphoma – opportunities for changing practice

Year:

Session type:

Bruce D. Cheson1
1Georgetown Lombardi Comprehensive Cancer Center, Washington, USA

The use of prognostic tools in palliative care

Year:

Session type:

Paddy Stone1
1St George's University, London, UK

Reduced intensity allogeneic transplantation for relapsed lymphoma

Year:

Session type:

Stephen Mackinnon1
1University College Hospital, London, UK

Dialogues to improve end of life care: prognostication and advance care planning

Year:

Session type:

Jane Seymour1
1University of Nottingham, Nottingham, UK

Late treatment effects in patients with lymphoma – their impact on the duration and quality of survival

Year:

Session type:

Flora van Leeuwen1
1The Netherlands Cancer Institute

Diagnosing dying: Findings of a European Collaborative Study OPCARE9

Year:

Session type:

John Ellershaw1
1University of Liverpool & Marie Curie Palliative Care Institute

Introduction:  Liver and colorectal cancer

Year:

Session type:

Tim Maughan1
1Gray Institute for Radiation Oncology and Biology, Oxford, UK

The tumour vasculature in metastatic CRC: Beyond the obvious

Year:

Session type:

Lee Ellis1
1MD Anderson Cancer Center, Houston, Texas, USA

Exploiting knowledge of DNA damage repair to improve treatment for patients with colorectal cancer

Year:

Session type:

Ricky Sharma1
1University of Oxford, Oxford, UK